Xanthine

Holiday Pet Dangers

Retrieved on: 
Wednesday, November 15, 2023
CNS, Xanthine, Holiday, Vomiting, Poisoning, Pet, Urine, Blood pressure, Cat, Toxicity, THC, Toxicology, Coma, Risk, Tremor, Arrhythmia, Chocolate, Hypoglycemia, Xylitol, Metabolic acidosis, Ataxia, New Year's Eve, Milk, Heart rate, Animal, Acute liver failure, Oxycodone, Ethanol, Hypoventilation, Friends, Alaskan Malamute, Caffeine, Seizure, Golden, Kidney failure, Diarrhea, Survival, Death, Tachycardia, Happiness, Paracetamol, Classic, Family, Nightmare, Mouth, Sodium chloride, Central nervous system, Failure, Common, Dog, Hypothermia, Lethargy, Radar, Theobromine, Fireworks, Liquor, Tourism, Makita

MINNEAPOLIS, Nov. 15, 2023 /PRNewswire/ -- The holidays are best spent with family and friends, not taking a trip to the animal hospital. With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.

Key Points: 
  • With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.
  • Meinke also contacted Pet Poison Helpline, who then worked with the medical team at BluePearl to identify the lily, diagnose and treat his pets.
  • "Many holiday treats include chocolate, and are often left sitting out on counters and dinner tables," said Dr. Schmid.
  • This year, we want pet lovers to remember the holidays for all the joy and happiness, not an emergency room visit."

XORTX Presents New Proof of Concept Data at American Society of Nephrology

Retrieved on: 
Thursday, November 3, 2022
Xanthine oxidase, Kidney, International, Society, Uric acid, Coronavirus, Mouse, University, OXO, Cyst, Analysis, Form, SEC, Nephrology, Diabetes, Hyperuricemia, Growth, GLOBE, Incidence, Fibrosis, Autosome, CEO, Health, DS, Xanthine, Allantoin, Diagnosis, Polycystic kidney disease, Patient, TSX Venture Exchange, Research, Unitary state, University of Colorado Denver School of Public Affairs, Letter, Human, Quality of life, COVID-19, HIV disease progression rates, Life, No, Kidney disease, Urate oxidase, Conference, Abstract, Therapy, Nasdaq, Session, ASN, American Society of Nephrology, Chronic pain, NASDAQ, News, Association, Pharmaceutical industry, Sulfur, Gum arabic, ADPKD, Kidney stone disease, PKD, Creatinine

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the presentation of a peer-reviewed abstract to be presented November 4, 2022 at the American Society of Nephrology (“ASN”) Annual Conference – Kidney Week.  The abstract presents new discoveries in two species – mouse and rat models of polycystic kidney disease (“PKD”) and reports original work showing the harmful consequence of chronically increased uric acid on both structure and function of kidneys. The Abstract “Raising Serum Uric Acid with a Uricase Inhibitor Worsens PKD in Rat and Mouse models” will be presented during the Session Title: Genetic Diseases of the Kidneys, by Dr. Charles Edelstein of the University of Colorado and Dr. Allen Davidoff, CEO of XORTX.  This presentation will report for the first time, that XORTX's XRx-008 formulation of Xanthine Oxidase inhibitor can substantially and significantly block the increase in kidney size associated with high circulating uric acid in a rodent model of polycystic kidney disease.

Key Points: 
  • The abstract presents the findings of studies conducted at the University of Colorado, by Dr. Charles Edelstein and the PKD research team.
  • Dr. Allen Davidoff, CEO of XORTX, stated, We are pleased to present these important new findings during the ASN Kidney Week 2022.
  • With these results presented today, XORTX now has the information required to prepare and pursue Orphan Drug Designation for XRx-008.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.

LG Chem Enters Final Stage of Clinical Development for New Gout Drug

Retrieved on: 
Wednesday, August 3, 2022
Science, Other Science, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, LG Chem, Inborn errors of metabolism, US FDA, LG, Comparison, Month, Gout, Xanthine, Patient, Company, Lists of diseases, Diabetes, Safety, Ageing, Hyperuricemia, IND, Adult, Uric acid, Population, Pharmaceutical industry

LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug Tigulixostat (clinical program name: EURELIA_1 Study).

Key Points: 
  • LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug Tigulixostat (clinical program name: EURELIA_1 Study).
  • Additionally, LG Chem will be submitting an application to the US FDA for a comparative study with Allopurinol, a first line treatment of gout.
  • LG Chem aims to enter the global gout market in 2028 after obtaining US FDA approval for Tigulixostat as a first line treatment.
  • LG Chem Life Sciences is a business division within LG Chem, engaged in development, manufacturing and global commercialization of pharmaceutical products.

Xanthine Oxidase Inhibitor Pipeline Insights, 2019 Market Report Featuring Fuji Yakuhin, Sanwa Kagaku Kenkyusho, LG Life Sciences, Ardea Biosciences, & Teijin Pharma - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 10, 2019
Health, Biotechnology, Enzymes, Chemistry, Physical sciences, Metalloproteins, Xanthine oxidase, Xanthine, Molybdenum, Drug pipeline

The "Xanthine Oxidase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Xanthine Oxidase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Xanthine Oxidase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Xanthine Oxidase Inhibitor development.
  • Descriptive coverage of pipeline development activities for Xanthine Oxidase Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
  • The report assesses the active Xanthine Oxidase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.